# An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

> **NCT02845674** · PHASE3 · COMPLETED · sponsor: **Sun Pharmaceutical Industries Limited** · enrollment: 258 (actual)

## Conditions studied

- Keratoconjunctivitis Sicca

## Interventions

- **DRUG:** OTX-101 0.09%

## Key facts

- **NCT ID:** NCT02845674
- **Lead sponsor:** Sun Pharmaceutical Industries Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-29
- **Primary completion:** 2017-08-15
- **Final completion:** 2017-08-15
- **Target enrollment:** 258 (ACTUAL)
- **Last updated:** 2021-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02845674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02845674, "An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02845674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*